A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Phase 2
- Conditions
- psoriasis
- Registration Number
- JPRN-jRCT2080221043
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization
-At randomization, moderate to severe psoriasis as defined by:
-PASI score of 12 or greater and,
-IGA score of 3 or greater and,
-Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater At screening and randomization
Exclusion Criteria
-Forms of psoriasis other than chronic plaque-type
-Drug-induced psoriasis at randomization
-Ongoing use of prohibited psoriasis treatments / medications at randomization.
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PASI 75 achievement(Time Frame: 12 weeks)
- Secondary Outcome Measures
Name Time Method IGA (Time Frame: 12 weeks)